表紙
市場調查報告書
商品編碼
983405

血友病的全球市場 (2020年∼2027年)

Global Hemophilia Market, Size, Share, Opportunities and Forecast, 2020-2027

出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

全球血友病市場的主要促進因素,有血友病患者的失血抑制需求增加,及集中性的研究開發活動的成果等。各治療法中的補充療法,尤其是血漿來源的凝固凝血因子濃縮劑佔著大佔有率,不過,由於有疾病感染風險,近來轉換到基因改造型的凝固凝血因子濃縮劑。各地區中北美各國成為最大的市場。

本報告提供全球血友病的市場相關分析,市場基本結構及最新形勢,整體市場趨勢預測 (今後8年份),疾病的各類型、各治療法、各產品種類及各地區詳細趨勢,主要的推動及阻礙市場要素,市場競爭結構,主要企業的簡介、事業策略等相關調查。

目錄

第1章 全球血友病市場:分析方法、範圍

第2章 全球血友病市場:市場定義和概要

第3章 全球血友病市場:摘要整理

第4章 全球血友病市場:市場動態

  • 對市場的影響要素
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 影響力分析

第5章 全球血友病市場:產業分析

  • 波特的五力分析
  • 供應鏈分析
  • 法規分析
  • 價格分析
  • 產品分析
  • 售後服務分析

第6章 全球血友病市場:疾病的各類型

  • 簡介
  • 市場規模的分析及與前一年同期相比成長率 (YoY):各原料
  • 市場向心力指數:各原料
    • A型血友病
    • B型血友病
    • 血友病C
    • 其他

第7章 全球血友病市場:各治療法

  • 簡介
  • 市場規模的分析及與前一年同期相比成長率 (YoY):各治療法
  • 市場向心力指數:各治療法
    • 補充療法
    • 基因治療
    • ITI (免疫寬恕引進療法)

第8章 全球血友病市場:各產品種類

  • 簡介
  • 市場規模的分析及與前一年同期相比成長率 (YoY):各產品種類
  • 市場向心力指數:各產品種類
    • 基因重組型凝血因子濃縮製劑
    • 血漿來源的凝血因子濃縮製劑
    • 其他

第9章 全球血友病市場:各地區

  • 簡介
  • 市場規模的分析及與前一年同期相比成長率 (YoY):各地區
  • 市場向心力指數:各地區
  • 北美
    • 簡介
    • 域內市場固有趨勢
    • 市場規模的分析及與前一年同期相比成長率 (YoY):疾病的各類型
    • 市場規模的分析及與前一年同期相比成長率 (YoY):各治療法
    • 市場規模的分析及與前一年同期相比成長率 (YoY):各產品種類
    • 市場規模的分析及與前一年同期相比成長率 (YoY):各國
  • 歐洲
  • 南美
  • 亞太地區
  • 中東、非洲

第10章 全球血友病市場競爭情形

  • 競爭模式
  • 市場定位/佔有率分析
  • 企業合併、收購 (M&A)的分析

第11章 全球血友病市場企業簡介

  • Bayer Healthcare
    • 企業概要
    • 產品的組合/概要
    • 近幾年趨勢
    • 財務分析:概要
  • Becton Dickinson & Company,
  • Biogen, Biotest AG
  • CSL Behring
  • Ferring B.V.
  • Genentech, Kedrion
  • Novo Nordisk
  • Octapharma
  • Pfizer
  • Sanofi SA
  • List is not exhaustive

第12章 全球血友病市場:重要考察

第13章 關於DataM Intelligence

目錄

Global Hemophilia Market is segmented By Disease Type (Hemophilia A, Hemophilia B, Hemophilia C, Others), By Therapy (Replacement Therapy, Gene Therapy, ITI therapy), By Product Type (Recombinant Coagulation, Factor Concentrates, Plasma-derived Coagulation, Factor Concentrates, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Share, Size, Outlook, and Opportunity Analysis, 2020-2027

Market Overview

The Global Hemophilia Market is expected to grow at a high CAGR of 5.5% during the forecasting period (2020-2027).

Hemophilia is an inherited bleeding disorder in which a person lacks or has low levels of certain proteins called "clotting factors" and the blood doesn't clot properly as a result. This leads to excessive bleeding. There are 13 types of clotting factors, and these work with platelets to help the blood clot. Platelets are small blood cells that form in your bone marrow. According to the World Federation of Hemophilia (WFH), about one in 10,000 people are born with this disease.

People with hemophilia bleed easily, and the blood takes a longer time to clot. People with hemophilia can experience spontaneous or internal bleeding and often have painful, swollen joints due to bleeding into the joints. This rare but serious condition can have life-threatening complications. 

The extent of the symptoms depends on the severity of your factor deficiency. People with a mild deficiency may bleed in the case of trauma. People with a severe deficiency may bleed for no reason.  For instance, the NHF (National Hemophilia Foundation) allows to find treatments for inheritable bleeding disorders and help prevent complications of these disorders through research, education, and advocacy. Their programs and initiatives are in association with the Centers for Disease Control and Prevention.

Market Dynamics

The market is driven is the rising need of hemophilia medicines in order to cater to the crucial medicinal requirement to limit blood loss is one of the prime growth factor for the global hemophilia market. Also, unavailability of any firm cure that can completely eliminate the disorder from the body of patients is also influencing the growth of global hemophilia market. 

The growth of global hemophilia market is also attributed to the augmented focus on intense research and development in order to provide more efficient drugs for the patients. Major technological advancements in the healthcare sector is also one of the major parameter that is responsible for the growth of global hemophilia market. Finally, the race to capture maximum opportunities by the players is also a prime reason supporting the growth of global hemophilia market. 

About 400 babies are born with hemophilia each year in the United States. According to the World Health Organization (WHO), there is a bigger prominence in males than in females. About 1/3rd of new diagnoses are where there is no earlier family history. It appears worldwide and is observed across all racial groups. About 6,000 people are suffering from hemophilia in the United Kingdom (as in 2018). There are approximately 5400 people in the UK with hemophilia A and about 1100 with hemophilia B. Hence the high prevalence of the disease is acting as one of the factors fueling the market growth all across the globe.

In addition, U.S. Hemophilia Treatment Center Network provides specialized healthcare centers and these offer care to address all psychological, educational, and physical needs of patients suffering from the disease. These centers currently provide care to more than 35,000 adults and children with the disease and other bleeding disorders.

Rising incidence of the disease is estimated to propel hemophilia market growth over the forecast period. According to the data published by the NHF, around 20,000 individuals in U.S. are suffering from this disease. In addition, approximately 75% of people with hemophilia receive inadequate treatment or have less/ no access to treatment globally.

However, high cost of treatment and lack of awareness regarding advanced technologies will hamper the growth of the market in the forecast period. 

Segment Analysis

The global hemophilia market is segmented based on disease type by hemophilia A, hemophilia B, hemophilia C and others. The hemophilia A segment held the largest market share. According to the National Hemophilia Foundation (NHF), the United States, the two major forms of hemophilia occur much more frequently in males than in females. Hemophilia A is the most prevalent type of condition with the incidence rate of 1 in 4,000 to 1 in 5,000 males worldwide who are born with this disorder. Whereas Hemophilia B occurs in approximately 1 in 20,000 newborn males all across the globe.  

People with hemophilia A often, bleed longer than other people. Bleeds can occur internally, into joints and muscles, or externally, from minor cuts, dental procedures or trauma. How frequently a person bleeds and the severity of those bleeds depends on how much FVIII is in the plasma, the straw-colored fluid portion of blood.

The key medication to treat hemophilia A has concentrated FVIII product, also called clotting factor or simply factor. Recombinant factor products that are developed in a laboratory through the use of DNA technology impede the use of human-derived pools of donor-sourced plasma. And while plasma-derived FVIII products are still available, approximately 75% of the hemophilia-affected community takes a recombinant FVIII product (as per the NHF). This factor will drive the growth of the market in the forecast period. 

The hemophilia B segment is expected to have positive market growth in the forecast period. Hemophilia B, also called factor IX (FIX) deficiency or Christmas disease, is a genetic disorder caused by missing or defective factor IX, a clotting protein. Although it is passed down from parents to children, about 1/3 of cases are caused by a spontaneous mutation, a change in a gene. 

According to the US Centers for Disease Control and Prevention, hemophilia occurs in approximately 1 in 5,000 live births. There are about 20,000 people with hemophilia in the US. All races and ethnic groups are affected. Hemophilia B is four times less common than hemophilia A.

People with hemophilia B bleed longer than other people. Bleeds can occur internally, into joints and muscles, or externally, from minor cuts, dental procedures or trauma. How frequently a person bleeds and how serious the bleeds are depends on how much FIX is in the plasma, the straw-colored fluid portion of blood.

Further, the market is also classified based on therapy as replacement therapy, gene therapy, ITI therapy. The replacement therapy segment is held the largest market share. The replacement therapy is to add clotting factor to a person's blood through an infusion with a clotting factor concentrate. There are two main types of clotting factor concentrates: recombinant factor concentrates and plasma-derived factor concentrates.

Plasma-derived factor concentrates are made from donated blood plasma, and in earlier decades were the only option for this type of replacement therapy. While these products undergo extensive screenings and procedures to prevent the spread of viruses and blood-borne diseases, the possibility of being exposed to a disease from a blood product still exists, which makes them a less attractive option for many patients and healthcare providers. Plasma-derived products have been used less frequently since recombinant products have become available. Recombinant factor concentrates are made in a lab using genetic engineering techniques and are considered the better option.

A clinician can also pre-implant a device in a patient so the patient has access to a vein more easily when administering their replacement therapy. The doctor can explain how to keep the device sterile and reduce the risk of infection. This factor would drive the growth of the market in the forecast period.

Geographical Presentation

By region, the hemophilia market is segmented into North America, South America, Europe, Asia-Pacific, Middle-East, and Africa. Among all of the regions, North America dominated the global hemophilia market and is expected to grow at the highest CAGR during the forecast period due to major technological advancements that are driving the healthcare sector in the region. 

NHF (National Health Federation) is an organization that has been awarding grants and fellowships in order to support innovative research intended for finding better treatments and cures for several bleeding disorders. Such researches have led to vital insights into improved factor replacement therapies, along with more accurate hemophilia diagnostic methods and therefore definitely a greater understanding of the genetic basis of the disease. 

Through the efforts and guidance of NHF's Medical and Scientific Advisory Council (MASAC), an internationally distinguished group of expert scientists, physicians as well as other treatment specialists, NHF has been engaged since long in advancing the standard of clinical care and issuing treatment recommendations for hemophilia.

Moreover, NHF states that the number of people with hemophilia in the United States is estimated to be about 20,000 individuals in 2019. Hence, owing to the rising prevalence of the disease along with the growing initiatives by several organizations is driving the market growth in the region. 

The Asia-Pacific region is expected to have third-largest share due to presence of a large patient pool, availability of skilled technicians at a comparatively lower price, and a defined regulatory framework favoring expedited product approvals. Furthermore, the booming medical tourism industry in countries such as India, China, and Malaysia are expected to boost demand for the treatment. These factors stimulate market growth over the forecasted period in the region. 

Competitive Analysis 

The hemophilia market is highly competitive with the presence of several international and local markets. Product diversification, revenue generation, and opportunities intensify the market competition Bayer Healthcare, Biogen, Biotest AG, CSL Behring, Ferring B.V., Genentech, Kedrion, Novo Nordisk, Octapharma, Pfizer, Sanofi SA, are the leading market players with significant market share. The major players are using product development, novel product launches, market expansion, and product diversification strategies for holding their position in the market. 

The companies are entering into collaborations, mergers, strategic partnerships, and acquisitions to expand their presence and meet the rising demand for the medical hemophilia market across the globe. For instance, BioMarin is involved in developing Valoctocogene Roxaparvovec (BMN-270) for treating type A patients and is currently under clinical trials.

In June 2017, the U.S. FDA accepted the investigational new drug application for Sanofi's BIVV001 based on its preclinical study results.

In March 2016, Baxalta filed a marketing authorization application for Adynovi with EMA. This application is under regulatory evaluation in Switzerland. Once completed, the company shall have all the marketing right for the product of Aynovi.

Why Purchase the Report?

Visualize the composition of the global hemophilia market products in terms of disease type, therapy and application and product type the critical commercial assets and players. 

Identify commercial opportunities in the global hemophilia market by analyzing trends and co-development deals. 

Excel data sheet with thousands of data points of global hemophilia market-level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study. 

  • *The global hemophilia market report will provide access to approximately 61 market data tables, 54 figures, and 200 pages   

Target Audience 2022

Industry Investors/Investment Bankers

Suppliers/Buyers

Education & Research Institutes

Manufacturers

Research Professionals

Emerging Companies

Distributors

Related Topic's

Lyme Disease Diagnostics Market

Fabry Disease Treatment Market

Table of Contents

Table of Contents

Global Hemophilia Market Methodology and Scope

Research Methodology

Research Objective and Scope of the Report

Global Hemophilia Market - Market Definition and Overview

Global Hemophilia Market - Executive Summary

Market Snippet by Disease Type

Market Snippet by Therapy

Market Snippet by Product Type

Market Snippet by Region

Global Hemophilia Market Dynamics

Market Impacting Factors

Drivers

Growing Prevalence of Hemophilia

Rising R&D and New Product Development

Restraints

High Cost of Treatment

Impact Analysis

Opportunity

Global Hemophilia Market - Industry Analysis

Porter's Five Forces Analysis

Supply Chain Analysis

Regulatory Analysis

Pricing Analysis

Product Analysis

Post Sales Services Analysis

Global Hemophilia Market - By Disease Type

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type

Market Attractiveness Index, By Disease Type

Hemophilia A *

Introduction

Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2019-2027

Hemophilia B

Hemophilia C

Others

Global Hemophilia Market - By Therapy

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy

Market Attractiveness Index, By Therapy

Replacement Therapy

Introduction

Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2019-2027

Gene Therapy

ITI therapy

Global Hemophilia Market - By Product Type

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type

Market Attractiveness Index, By Product Type

Recombinant Coagulation

Introduction

Market Size Analysis, US$ Mn, 2016-2025 and Y-o-Y Growth Analysis (%), 2019-2027

Factor Concentrates

Plasma-derived Coagulation

Factor Concentrates

Others

Global Hemophilia Market - By Region

Introduction

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region

Market Attractiveness Index, By Region

North America

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

U.S.

Canada

Mexico

Europe

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

Germany

U.K.

France

Rest of Europe

South America

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

Brazil

Argentina

Rest of South America

Asia Pacific

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

China

India

Japan

Australia

Rest of Asia Pacific

Middle East and Africa

Introduction

Key Region-Specific Dynamics

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Therapy

Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product Type

 Global Hemophilia Market Competitive Landscape

Competitive Scenario

Market Positioning/Share Analysis

Mergers and Acquisitions Analysis

Global Hemophilia Market Company Profiles

Bayer Healthcare*

Company Overview

Product Portfolio and Description

Key Developments

Financial Overview

Becton Dickinson & Company,

Biogen, Biotest AG

 CSL Behring

 Ferring B.V.

 Genentech, Kedrion

 Novo Nordisk

 Octapharma

 Pfizer

Sanofi SA (*List is not exhaustive)

Global Hemophilia Market - Premium Insights

Global Hemophilia Market - DataM

Appendix

About Us and Services

Contact Us